close
close

GLP-1 RA intake leads to lower hyperkalemia rates in type 2 diabetes


GLP-1 RA intake leads to lower hyperkalemia rates in type 2 diabetes

MONDAY, Aug. 12, 2024 (HealthDay News) — Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with lower rates of hyperkalemia and a lower rate of discontinuation of renin-angiotensin system inhibitors (RASi) compared with treatment with dipeptidyl peptidase-4 inhibitors (DPP-4is) in patients with type 2 diabetes (T2D), according to a study published online Aug. […]